High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Conditions
Interventions
Concurrent Chemoradiotherapy:None
Nimotuzumab Combined with Concurrent Chemoradiotherapy:None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Histopathological diagnosis of HNSCC. 2. Age between 20 and 70 years. 3. ECOG score of 0-1. 4. Adequate hematological, renal, and hepatic function. 5. All patients underwent radical surgical treatment. 6. All patients received adjuvant concurrent chemoradiotherapy or concurrent chemoradiotherapy combined with nimotuzumab. 7. AJCC (8th edition) locally advanced squamous cell carcinoma of the head and neck: III, IVA, and IVB. 8. All patients had one or more of the following high-risk factors, such as T3-4, N2-3, lymph nodes located in level IV or V, vascular invasion, perineural invasion, positive or close margins, and extracapsular spread of lymph nodes. 9. The clinical medical records of the patients were complete.
Exclusion criteria
Exclusion criteria: 1. Nasopharyngeal carcinoma. 2. Allergy to nimotuzumab or its components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Safety; | — |
Countries
China
Contacts
Public ContactTong Gangling
Peking University Shenzhen Hospital
Outcome results
None listed